Attached files
For immediate release
Global Green, Inc. Initiates Advanced Trial in Quest of
Salmonella-Free Egg
FDA announced new regulation in effort to promote egg safety Tallahassee,
Fla - August 8, 2012 - Global Green, Inc. (OTCBB:GOGC) announced today that the
Company has initiated an advanced trial for its patented, exclusively-licensed
vaccine, Salmogenics. The purpose of the study is to determine how long a
chicken can be protected against Salmonella after it begins laying eggs. If a
layer hen is not infected with the Salmonella bacteria, then neither the egg,
nor the chick, when it hatches, will have Salmonella. There is a "timelined"
vaccine effect that will be logged and sequenced during the study, beginning
from a newly-hatched chicken, to the 18-20 weeks before the chicken becomes a
layer hen, and, after that, until the end of the hen's productive life.
Currently, Salmogenics has proven effective in helping to combat multiple
strains of Salmonella in broilers, chickens produced for consumption. In the
U.S. alone, The National Chicken Council reported in 2011 that 9 billion broiler
chickens were produced. The Vaccine is currently in the final stage of the USDA
approval process.
The most recent estimate by Global Industry Analysts predicts that the global
market for eggs is estimated to reach 1,154 billion by the year 2015. Tests
conducted through third parties have found that Salmogenics has been shown to
significantly reduce Salmonella in the egg. Ongoing tests will be conducted to
determine the efficacy of reducing Salmonella in egg-laying hens. By combining
Salmogenics with the preventive measures that the USDA has mandated, management
believes that Salmonella could potentially be reduced in the egg industry and
that the vaccine's market potential could be expanded significantly.
On July 9, 2012, the Food and Drug Administration (FDA) announced a regulation
expected to prevent approximately 79,000 cases of foodborne illness and
associated deaths each year caused by consumption of eggs contaminated with the
bacterium Salmonella enteritidis. The rule specifically addresses the presence
of Salmonella in the shell of the eggs as the Salmonella bacteria can invade the
egg through the shell after the egg is laid.
Salmogenics is injected directly into the egg, before the chick is hatched,
improving the immune system, health and welfare of the chicken, and providing a
healthier source of protein for humans in a cost effective manner. From the egg
injected with Salmogenics, either a broiler or an egg laying hen is hatched.
Once hatched, either of these would be expected to show a significant reduction
in the presence of Salmonella or could essentially be Salmonella-free for a
given period of time. The planned study would confirm how long the egg-laying
hen would be protected from Salmonella, and if a "booster" injection would be
required.
"The new regulation as mandated by the FDA is an important step in the public
health strategy. The facts show that Salmonella is a hazard we can and should
address. Salmogenics shows great potential in becoming an essential tool for
producing a "zero tolerance for Salmonella" egg. Global Green is excited about
being part of the solution," commented Dr. Mehran Ghazvini, Chairman and CEO of
Global Green.
According to the FDA, "egg-associated illness caused by Salmonella is a serious
public health problem. Infected individuals may suffer mild to severe
gastrointestinal illness, short term or chronic arthritis, or even death.
Implementing the preventive measures would reduce the number of Salmonella
enteritidis infections from eggs by nearly 60 percent." Global Green, Inc. is a
green pharmaceutical company committed to identifying technology platforms and
commercializing products that contain natural organisms that are not genetically
modified, utilizing pharmaceutical standards. Salmogenics, the Company's
flagship product, was developed by Nutritional Health Institute Laboratories,
LLC, a research affiliate and majority shareholder. The vaccine is currently in
the final stage of the USDA approval process. For more information, visit
www.globalgreeninc.org.
Forward-Looking Statement
This press release may contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned
that such forward-looking statements involve risks and uncertainties, which
include among others, the inherent uncertainties associated with smaller
reporting companies, including without limitation, other risks detailed from
time to time in the Company's periodic reports filed with the Securities and
Exchange Commission.
Contact:
Pam Lagano
plagano@globalgreeninc.org
727.480.308